--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-027965" form_type: "8-K" ticker: "VKTX" cik: "0001607678" company_name: "Viking Therapeutics, Inc." filed_at: "2023-06-14T23:59:59+00:00" generated_at: "2026-06-14T01:15:33.755943+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.35 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Viking Therapeutics shareholders reelect directors, ratify auditor, reject officer exculpation amendment ## Summary - Elected J. Matthew Singleton and S. Kathy Rouan as Class II directors to serve until 2026 annual meeting. - Ratified Marcum LLP as independent registered public accounting firm for FY2023 (76.6M for, 173k against). - Advisory vote on named executive officer compensation passed (53.4M for, 1.3M against, 22.1M broker non-votes). - Amendment to certificate of incorporation for officer exculpation under Delaware law failed; received 52.8M votes for (53% of outstanding), needed 66.7% of all shares. ## SEC filing metadata - accession: 0000950170-23-027965 - form_type: 8-K - ticker: VKTX - cik: 0001607678 - company_name: Viking Therapeutics, Inc. - filed_at: 2023-06-14T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.35 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/vktx-20230613.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-027965 - JSON: https://secwatch.observer/filing/0000950170-23-027965.json - Plain text: https://secwatch.observer/filing/0000950170-23-027965.txt ## Key facts - Shareholder Votes Viking Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2023-06-13 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-13 source text: Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 53,378,794 1,290,698 119,550 22,089,470 As a result, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm - Shareholder Votes Viking Therapeutics, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023. at the 2023-06-13 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-13 source text: Proposal No. 2. To ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 76,559,286 173,191 146,035 As a result, the Company’s stockholders voted to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm - Shareholder Votes Viking Therapeutics, Inc. shareholders approved Election of J. Matthew Singleton and S. Kathy Rouan, Ph.D. as Class II directors. at the 2023-06-13 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-13 source text: Proposal No. 1. To elect the following nominees as Class II directors to serve until the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Director Nominee Votes For Votes Withheld Broker Non-Votes J. Matthew Singleton 37,468,639 17,320,403 22,089,470 S. Kathy Rouan, Ph.D. 42,477,215 12,311,827 22,089,470 As a result, the Company’s stockholders voted to elect J. Matthew Singleton and S. Kathy Rouan, Ph.D. as Class II directors to serve until the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm - Shareholder Votes Viking Therapeutics, Inc. shareholders rejected Approval of an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2023-06-13 meeting. - Proposal: charter amendment - Outcome: failed - Meeting: 2023-06-13 source text: Proposal No. 4. To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation: Votes For Votes Against Abstentions Broker Non-Votes 52,790,076 1,819,594 179,372 22,089,470 In order to be approved, this proposal required the affirmative vote of at least 66 2/3% of the voting power of all outstanding shares of the Company’s capital stock entitled to vote thereon. As a result, the Company’s stockholders did not approve the amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.